ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Andréa Witz
Matched on ORCID iD 0000-0002-1131-5193; OpenAlex author ID A5023920977. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers
Papers 8
- Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. Co-author DOI 10.1016/j.ijrobp.2025.09.013↗
- Radiotherapy in the management of PDAC, from past to present. Co-author DOI 10.1016/j.tranon.2025.102632↗
- Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
- DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. First author DOI 10.1038/s41420-024-02188-9↗
- CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines. Co-author DOI 10.1038/s41598-023-45964-w↗
- DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. First author DOI 10.3389/fonc.2022.1052163↗
- Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. First author DOI 10.3390/ph14080740↗
- SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms21103534↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alexandre Harlé · 8 shared papers, 2020–2026 · strength 1.64
- Paper Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. DOI 10.1016/j.ijrobp.2025.09.013↗
- Paper Radiotherapy in the management of PDAC, from past to present. DOI 10.1016/j.tranon.2025.102632↗
- Paper Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From t… DOI 10.1200/jco-25-02508↗
- Pauline Gilson · 7 shared papers, 2020–2026 · strength 1.41
- Paper Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. DOI 10.1016/j.ijrobp.2025.09.013↗
- Paper Radiotherapy in the management of PDAC, from past to present. DOI 10.1016/j.tranon.2025.102632↗
- Paper DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. DOI 10.1038/s41420-024-02188-9↗
- Julie Dardare · 7 shared papers, 2020–2026 · strength 1.41
- Paper Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. DOI 10.1016/j.ijrobp.2025.09.013↗
- Paper Radiotherapy in the management of PDAC, from past to present. DOI 10.1016/j.tranon.2025.102632↗
- Paper DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. DOI 10.1038/s41420-024-02188-9↗
- Aurélien Lambert · 5 shared papers, 2022–2026 · strength 1.16
- Paper Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. DOI 10.1016/j.ijrobp.2025.09.013↗
- Paper Radiotherapy in the management of PDAC, from past to present. DOI 10.1016/j.tranon.2025.102632↗
- Paper Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From t… DOI 10.1200/jco-25-02508↗
- Thierry Conroy · 1 shared paper, 2026 · strength 0.23
- Rémy Nicolle · 1 shared paper, 2026 · strength 0.23
- James Biagi · 1 shared paper, 2026 · strength 0.23
- Anthony Turpin · 1 shared paper, 2026 · strength 0.23
- Jerome F. Cros · 1 shared paper, 2026 · strength 0.23
- Daniel John Renouf · 1 shared paper, 2026 · strength 0.23
- Juan Iovanna · 1 shared paper, 2026 · strength 0.23
- Pascal R. Hammel · 1 shared paper, 2026 · strength 0.23
- Jean‐Baptiste Bachet · 1 shared paper, 2026 · strength 0.23
- Nelson Dusetti · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.